ARNTL2-AS1

Across TCGA pan-cancer cohorts, ARNTL2-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ARNTL2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where ARNTL2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARNTL2-AS1 is over-expressed in tumor.

LUSC, COAD, and READ are the cancer types where ARNTL2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARNTL2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Male	II,III,IV	+0.460	<.001	9	view →
COAD	All	II,III,IV	+0.171	<.001	6	view →
READ	All	All	+0.180	.004	4	view →
LUAD	All	III,IV	+0.151	.005	4	view →
LIHC	All	II,III,IV	+0.045	.016	3	view →
CHOL	Male	All	+0.203	.024	2	view →
HNSC	Male	II,III,IV	+0.118	.036	2	view →
THCA	Male	III,IV	+0.107	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ARNTL2-AS1–LUSC

Open the LUSC breakdown →